Drug Profile
Research programme: ephrin (EphA2) receptor antagonists - Pfizer
Alternative Names: EphA2 receptor tyrosine kinase inhibitor (Compound A) - PfizerLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Pfizer
- Class Small molecules
- Mechanism of Action EphA2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA
- 22 Apr 2009 Preclinical trials in Cancer in USA (unspecified route)